Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

mirror_world_man 3 posts  |  Last Activity: Mar 25, 2015 3:39 PM Member since: Mar 23, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    FDA agrees on SVC primary endpoint

    by aecooter33 Mar 25, 2015 12:14 PM
    mirror_world_man mirror_world_man Mar 25, 2015 3:39 PM Flag

    One important lesson from the B-ALS is to keep energy levels up, the trial population remains well fed during the Phase 3. No empty calories...

    Sentiment: Strong Buy

  • Reply to

    The news release

    by warrenw6630 Mar 25, 2015 10:02 AM
    mirror_world_man mirror_world_man Mar 25, 2015 1:31 PM Flag

    The knee jerk is not unusual in heavily shorted BT's of which CYTK is not, so it is a bit odd. I guessed the move to PIII was giving some BB's the tizzies of an offering to pay for the trials, or some people want in at a lower price. The results look ok after only a single dose. IMHO the bottom line is that those that dumped did so on automatic pilot, or have a longer range plan. I nibbled a bit on the way down, there is no harm as far as I can see.

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man Mar 21, 2015 5:22 PM Flag

    Stocks that warrant a look in the health care sector include Cytokinetics, Inc. CYTK, Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX. All of these carry a Zacks Rank #1 (Strong Buy). 2013 they said the same thing and CYTK popped to almost double a little later.

    Sentiment: Strong Buy

INCY
107.340.00(0.00%)Apr 24 4:00 PMEDT